Ting-Shu Wu, M.D. Infection Control Committee Infect Dis, Int Med, Chang Gung Memorial Hospital, Linkou Medical Center, Tao-Yuan, Taiwan
|
|
- Vernon Perkins
- 6 years ago
- Views:
Transcription
1 Ting-Shu Wu, M.D. Infection Control Committee Infect Dis, Int Med, Chang Gung Memorial Hospital, Linkou Medical Center, Tao-Yuan, Taiwan
2 NTM Other than M. tuberculosis, M. africanum, M. bovis, M. caprae, M. microti, M. canettii, M. mungi, M. orygis, and M. pinnipedii (M. tuberculosis complex), and M. leprae. Previous names: atypical mycobacteria, mycobacteria other than M. tuberculosis (MOTT)
3 Taxonomic Tree M. tuberculosis complex Mycobacteriaceae Mycobacterium M. leprae Nocardia NTM Actinomycetales Actinomycetaceae Actinomyces Streptomycetaceae Streptomyces S. griseus S. mediterranei
4 Currently recognized species of the genus Mycobacteria isolated form humans Group Obligatory Facultative Potential Saprophyte Strict pathogens Photochromogens M. africanum M. leprae M. tuberculosis M. ulcerans M. bovis M. asciaticum M. kansasii M. marinum M. simiae Scotochromogens M. scrofulaceum M. szulgai M. xenopi Nonchromogens M. genavense M. avium M. haemophilum M. intracellulare M. malmoense M. shimoidei Rapid growers Strict animal pathogens M. farcinogens M. lepraemurium M. porcinum M. chelonae M. fortuitum M. microti M. paratuberculosis M. senegalense M. gordonae M. flavescens M. gastri M. nonchromogenicum M. terrae M. triviale M. fallax M. smegmatis M. agri..
5 Runyon classification Class I (photochromogens) Class II (scotochromogens) Class III (nonchromogens) Class IV ( rapid growers)
6 Structure A: plasma membrane B: complex polymer C: peptidoglycans D: arabinogalactans E: mycolic acids F: methoxy type & keto type G: glycolipid H: lipoarabinomannan
7 Microbiology Acid fast stain Ziehl-Neelson stain (dry stain), or Kinyoun stain (wet stain) Fluorescent staining Culture: 7H9 (broth), 7H11 (agar), Löwenstein-Jensen medium (slant), MGIT 960 (Mycobacteria Growth Indicator Tube)
8 Manual of Clinical Microbiology, Vols. 1 and 2: Eighth Edition
9 RFLP (Telenti et al.)
10 MALDI-TOF/MS Matrix-Assisted Laser Desorption/ Ionization Time of Flight Mass Spectrometry
11 Slowly Growing Mycobacteria
12 Mycobacterium avium complex At present, the M avium complex M avium M intracellulare M chimaera (MAC-A) M colombiense (MAC-X) M vulneris (MAC-Q) M marseillense M timonense M bouchedurhonense M arosiense Claudio Piersimoni, Claudio Scarparo Lancet Infect Dis 2008; 8: Manual of Clinical Microbiology 11/e
13 Mycobacterium avium M. avium subsp. avium M. avium subsp. silvarticum M. avium subsp. paratuberculosis M. avium subsp. hominissuis
14
15 Mycobacterium avium complex M. intracellulare represents about 70% of M. avium complex isolates and its prognosis appears to be slightly more favourable than that of M. avium disease.
16 PROPHYLAXIS AGAINST DISSEMINATED MYCOBACTERIUM AVIUM COMPLEX WITH WEEKLY AZITHROMYCIN, DAILY RIFABUTIN, OR BOTH Weekly azithromycin is a simple, highly effective prophylactic regimen. The combination of azithromycin and rifabutin is more efficacious, but its use may be limited by its tolerability and cost and by potential drug interactions. Havlir DV et al. N Engl J Med 1996;335:
17 Regimens for the treatment of disseminated MAC disease in patients with HIV infection Preferred regimens CLR 500 BID + EMB 15 mg/kg QD (+RFB 300 QD) AZI 600 QD + EMB 15 mg/kg QD (+RFB 300 QD) Additional drugs for macrolideresistant infections Moxifloxacin 400 QD, or Levofloxacin mg QD + EMB 15 mg/kg QD + RFB 300 QD + AMK mg/kg QD
18 Mycobacterium avium complex Primary prophylaxis : azithromycin alone > rifabutin alone at reducing the incidence of MAC at 1 year in HIV positive people. Azithromycin or rifabutin alone < AZI+RFB Mortality: AZI = RFB = AZI+RFB ADR: AZI < AZI+RFB Jakko van Ingen et al. AJRCCM Am J Respir Crit Care Med Sep 15;186(6):
19 Mycobacterium kansasii Tenosynovitis
20 Mycobacterium kansasii
21
22
23 Mycobacterium marinum Wu TS et al. PLoS ONE. 2012;7(7):e41296
24 Wu TS et al. PLoS ONE. 2012;7(7):e41296
25 Wu TS et al. PLoS ONE. 2012;7(7):e41296
26 Figure 1. Cutaneous manifestations of Mycobacterium marinum infections. Wu T-S, Chiu C-H, Yang C-H, Leu H-S, et al. (2012) Fish Tank Granuloma Caused by Mycobacterium marinum. PLoS ONE 7(7): e doi: /journal.pone
27 Treatment regimens Species Disease Drug Dose Duration M. avium complex Pulmonary CLR+EMB +RIF or RFT Disseminated, HIV+ LAP, children CLR+EMB +RFT Surgery, CLR+RFT, OR EMB 500 bid, 15 mg/kg, 600 mg, mg 500 bid, 15 mg/kg, 300 mg Until negative culture for 12 mo For life?
28 Treatment regimens (2) Species Disease Drug Dose Duration M. Kansasii pulmonary INH+RIF +EMB?? disseminated same 300, 600, 15 mg/kg same 18 mo, culture negative for 12 mo HIV+ RIF RFB
29 Treatment regimens (3) Species Disease Drug Dose Duration M. marinum cutaneous CLR or minocycline or RIF+EMB 500 bid, 100 bid, 600, 15 mg/kg At least 3 mo
30 Rapidly Growing Mycobacteria
31 RGM Grow within 7 days on laboratory media. M. fortuitum group M. chelonae/m. abscessus group M. mucogenicum group M. smegmatis group Early-pigmented group M. mageritense/m. wolinskyi group
32 Breakpoints of RGM S I R AMK <16 32 >64 FOX < >128 CIP <1 2 >4 CLR <2 4 >8 DOX <1 2-4 >8 IPM < >32 LZD <8 16 >32 MEM < >32 MXF <1 2 >4 SXT <2/38 >4/76 TOB <2 4 >8
33 ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Oct. 2002, p
34 CID 2006:42 (15 June) 1759
35 Clincal significance Common in environment Most identified in tap water M. fortuitum, M. abscessus, M. chelonae for > 80%
36 Clincal significance Skin and soft tissue infections Disseminated cutaneous disease Bone and joint infections Pulmonary infections Central nervous system disease Corneal infections Otitis media Health care-associated infections
37 M. abscessus sensu lato M. abscessus sensu stricto M. massiliense M. bolletii
38 Mycobacterium abscessus M. abscessus M. abscessus subsp. abscessus M. massiliense and M. bolletii M. abscessus subsp. bolletii
39 Mother Daughter
40 M Mo D1 D2 D Kb Lin CY, Hsu CY, Wu TS et al. Unpublished data
41 Before After
42 Antibiotic susceptibility and efficacy Modal MICs are below the tissue or serum levels only for clarithromycin, aminoglycosides, cefoxitin, tigecycline and TMC-207. Recommendations are now to combine clarithromycin with one aminoglycoside (usually amikacin) and one other injectable drug such as cefoxitin or imipenem. Clinical efficacy of this multidrug therapy is still controversial, with success for some patients and failure for others
43 Natural resistance The mycobacterial cell envelope Antibiotic-modifying / inactivating enzymes Target-modifying enzymes Efflux pumps Transcriptional regulator whib gene family Genetic polymorphism of target genes Mercury resistance
44 Macrolide resistance Bacterial resistance to macrolides occurs by posttranscriptional methylation of the 23S bacterial ribosomal RNA, thereby inhibiting drug attachment This acquired resistance results in crossresistance to macrolides, lincosamides and streptogramins Resistance to macrolides acquired by mutation in the rrl gene encoding the 23S rrna generally occurs in mycobacterial species
45 M. abscessus group: M. abscessus (sensu stricto), M. massiliense and M. bolletii M. massiliense, which harbours a truncated erm(41) gene, is intrinsically susceptible to clarithromycin, whereas M. abscessus sensu stricto contains a complete erm(41) gene Strains identified as M. abscessus with a C28 polymorphism are associated with clarithromycin susceptibility, whereas a T28 polymorphism is associated with clarithromycin resistance. M. bolletii, which contains the T28 polymorphic erm(41) gene, was shown to be clarithromycin resistant
46 Case 1. erm(41) of M. massiliense ATCC19977 Soft tissue infection cases Wu T.-S. et al. JMII. Online published
47 Antibiotics for Rapid Growers Bacteria Parenteral Oral M. abscessus Amikacin, imipenem Clarithromycin, quinolones, sulfonamides M. chelonae Amikacin (tobramycin), imipenem Clarithromycin M. fortuitum Amikacin, cefoxitin Clarithromycin M. smegmatis Amikacin, imipenem Doxycycline, quinolones, sulfonamides
48 Thank you for your attention!
Treatment of Nontuberculous Mycobacterial Infections (NTM)
Treatment of Nontuberculous Mycobacterial Infections (NTM) Charles L. Daley, MD National Jewish Health University of Colorado, Denver Disclosures Investigator Insmed (inhaled liposomal amikacin) Advisory
More informationTreatment for NTM: when how.and what next? Pr Claire Andréjak Respiratory and ICU Department University hospital, Amiens, France
Treatment for NTM: when how.and what next? Pr Claire Andréjak Respiratory and ICU Department University hospital, Amiens, France First step = To diagnose NTM disease One NTM positive sample NTM disease
More informationTreatment of Slowly Growing NTM Infections
Treatment of Slowly Growing NTM Infections Charles L. Daley, MD National Jewish Health University of Colorado, Denver Disclosures Investigator Insmed (inhaled liposomal amikacin) Advisory Committee Insmed
More informationNon-Tuberculous Mycobacterial Pulmonary Disease Diagnosis and Management Jakko van Ingen, MD, PhD
Non-Tuberculous Mycobacterial Pulmonary Disease (NTM-PD) 1 Radbound University Nihmegen Medical Center Milestones in NTM research 1980s: Nodular bronchiectatic lung disease Lady Windermere syndrome 1882-1890
More informationSENSITITRE. Broth Microdilution (MIC) Method:
SENSITITRE Broth Microdilution (MIC) Method: For Rapidly Growing Mycobacteria (RGM), Slowly Growing Nontuberculosis Mycobacteria, Nocardia and other Aerobic Actinomycetes For Research Use Only For full
More information2/20/18
1 www.uthealth.org/microbiology 2/20/18 INTRODUCTION. Susceptibility testing, identification by DNA gene sequencing and DNA fingerprinting of the rapidly growing mycobacteria and other nontuberculous mycobacteria
More informationDM seminar. Pulmonary diseases due to NTM & their management
DM seminar Pulmonary diseases due to NTM & their management Content 1. Introduction 2. Microbiology 3. Epidemiology 4. Diseases 5. Diagnosis 6. Treatment 7. Individual species Introduction Genus Mycobacterium
More informationOriginal Article In vitro drug susceptibility of 40 international reference rapidly growing mycobacteria to 20 antimicrobial agents
Int J Clin Exp Med 2015;8(9):15423-15431 www.ijcem.com /ISSN:1940-5901/IJCEM0009773 Original Article In vitro drug susceptibility of 40 international reference rapidly growing mycobacteria to 20 antimicrobial
More informationEUCAST Expert Rules for Staphylococcus spp IF resistant to isoxazolylpenicillins
EUAST Expert Rules for 2018 Organisms Agents tested Agents affected Rule aureus Oxacillin efoxitin (disk diffusion), detection of meca or mec gene or of PBP2a All β-lactams except those specifically licensed
More informationProceedings of the World Small Animal Veterinary Association Sydney, Australia 2007
Proceedings of the World Small Animal Veterinary Association Sydney, Australia 2007 Hosted by: Australian Small Animal Veterinary Association (ASAVA) Australian Small Animal Veterinary Association (ASAVA)
More informationZyvox. Zyvox (linezolid) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.20 Subject: Zyvox Page: 1 of 7 Last Review Date: March 18, 2016 Zyvox Description Zyvox (linezolid)
More informationnumber Done by Corrected by Doctor Dr Hamed Al-Zoubi
number 8 Done by Corrected by Doctor Dr Hamed Al-Zoubi 25 10/10/2017 Antibacterial therapy 2 د. حامد الزعبي Dr Hamed Al-Zoubi Antibacterial therapy Figure 2/ Antibiotics target Inhibition of microbial
More informationResearch Article Drug Susceptibility Testing of 31 Antimicrobial Agents on Rapidly Growing Mycobacteria Isolates from China
BioMed Research International Volume 2015, Article ID 419392, 8 pages http://dx.doi.org/10.1155/2015/419392 Research Article Drug Susceptibility Testing of 31 Antimicrobial Agents on Rapidly Growing Mycobacteria
More informationCase Report Atypical Mycobacterial Infection after Abdominoplasty Overseas: A Case Report and Literature Review
Case Reports in Infectious Diseases Volume 2016, Article ID 3642567, 4 pages http://dx.doi.org/10.1155/2016/3642567 Case Report Atypical Mycobacterial Infection after Abdominoplasty Overseas: A Case Report
More informationMechanism of antibiotic resistance
Mechanism of antibiotic resistance Dr.Siriwoot Sookkhee Ph.D (Biopharmaceutics) Department of Microbiology Faculty of Medicine, Chiang Mai University Antibiotic resistance Cross-resistance : resistance
More informationReceived 8 May 1996/Returned for modification 8 July 1996/Accepted 23 August 1996
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Nov. 1996, p. 2483 2487 Vol. 40, No. 11 0066-4804/96/$04.00 0 Copyright 1996, American Society for Microbiology Spectrum of Activity of Levofloxacin against Nontuberculous
More informationSelective toxicity. Antimicrobial Drugs. Alexander Fleming 10/17/2016
Selective toxicity Antimicrobial Drugs Chapter 20 BIO 220 Drugs must work inside the host and harm the infective pathogens, but not the host Antibiotics are compounds produced by fungi or bacteria that
More informationRadiometric studies on the use of selective inhibitors in the identification of Mycobacteriurn spp.
J. Med. Microbiol. - Vol. 30 (1989), 175-181 989 The Pathological Society of Great Britain and Ireland 0022-2615/89/0030-0175/$10.00 Radiometric studies on the use of selective inhibitors in the identification
More informationNontuberculous mycobacteria in captive and pet reptiles
Nontuberculous mycobacteria in captive and pet reptiles Irena Reil, Silvio Špičić, Gordan Kompes, Sanja Duvnjak, Maja Zdelar-Tuk, Dora Stojević, Željko Cvetnić Croatian Veterinary Institute, Zagreb, Croatia
More informationBurton's Microbiology for the Health Sciences. Chapter 9. Controlling Microbial Growth in Vivo Using Antimicrobial Agents
Burton's Microbiology for the Health Sciences Chapter 9. Controlling Microbial Growth in Vivo Using Antimicrobial Agents Chapter 9 Outline Introduction Characteristics of an Ideal Antimicrobial Agent How
More informationInhibiting Microbial Growth in vivo. CLS 212: Medical Microbiology Zeina Alkudmani
Inhibiting Microbial Growth in vivo CLS 212: Medical Microbiology Zeina Alkudmani Chemotherapy Definitions The use of any chemical (drug) to treat any disease or condition. Chemotherapeutic Agent Any drug
More informationIntroduction to Chemotherapeutic Agents. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The university of Jordan November 2018
Introduction to Chemotherapeutic Agents Munir Gharaibeh MD, PhD, MHPE School of Medicine, The university of Jordan November 2018 Antimicrobial Agents Substances that kill bacteria without harming the host.
More informationAntimicrobials & Resistance
Antimicrobials & Resistance History 1908, Paul Ehrlich - Arsenic compound Arsphenamine 1929, Alexander Fleming - Discovery of Penicillin 1935, Gerhard Domag - Discovery of the red dye Prontosil (sulfonamide)
More informationIn Vitro Activities of Linezolid against Clinical Isolates of ACCEPTED
AAC Accepts, published online ahead of print on April 00 Antimicrob. Agents Chemother. doi:./aac.001-0 Copyright 00, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationMDR-TB drugs per WHO guidelines
New antituberculous agents for drug-resistant resistant TB Symposium Belgian Society of Infectiology and Clinical Microbiology November 9 Jens Van Roey, MD - Tibotec Definitions MDR-TB multidrug resistance
More informationAntibiotic resistance a mechanistic overview Neil Woodford
Antibiotic Resistance a Mechanistic verview BSc PhD FRCPath Consultant Clinical Scientist 1 Polymyxin Colistin Daptomycin Mechanisms of antibiotic action Quinolones Mupirocin Nitrofurans Nitroimidazoles
More informationAntibiotics. Antimicrobial Drugs. Alexander Fleming 10/18/2017
Antibiotics Antimicrobial Drugs Chapter 20 BIO 220 Antibiotics are compounds produced by fungi or bacteria that inhibit or kill competing microbial species Antimicrobial drugs must display selective toxicity,
More informationOutline. Antimicrobial resistance. Antimicrobial resistance in gram negative bacilli. % susceptibility 7/11/2010
Multi-Drug Resistant Organisms Is Combination Therapy the Way to Go? Sutthiporn Pattharachayakul, PharmD Prince of Songkhla University, Thailand Outline Prevalence of anti-microbial resistance in Acinetobacter
More informationThe pharmacological and microbiological basis of PK/PD : why did we need to invent PK/PD in the first place? Paul M. Tulkens
The pharmacological and microbiological basis of PK/PD : why did we need to invent PK/PD in the first place? Paul M. Tulkens Cellular and Molecular Pharmacology Unit Catholic University of Louvain, Brussels,
More informationSignificant difference in drug susceptibility distribution between Mycobacterium avium
JCM Accepts, published online ahead of print on 1 October 2014 J. Clin. Microbiol. doi:10.1128/jcm.02127-14 Copyright 2014, American Society for Microbiology. All Rights Reserved. 1 2 Significant difference
More informationPrinciples of Antimicrobial therapy
Principles of Antimicrobial therapy Laith Mohammed Abbas Al-Huseini M.B.Ch.B., M.Sc, M.Res, Ph.D Department of Pharmacology and Therapeutics Antimicrobial agents are chemical substances that can kill or
More informationJanuary 2014 Vol. 34 No. 1
January 2014 Vol. 34 No. 1. and Minimum Inhibitory Concentration (MIC) Interpretive Standards for Testing Conditions Medium: diffusion: Mueller-Hinton agar (MHA) Broth dilution: cation-adjusted Mueller-Hinton
More informationEuropean Committee on Antimicrobial Susceptibility Testing
European Committee on Antimicrobial Susceptibility Testing Routine and extended internal quality control as recommended by EUCAST Version 5.0, valid from 015-01-09 This document should be cited as "The
More informationAppropriate antimicrobial therapy in HAP: What does this mean?
Appropriate antimicrobial therapy in HAP: What does this mean? Jaehee Lee, M.D. Kyungpook National University Hospital, Korea KNUH since 1907 Presentation outline Empiric antimicrobial choice: right spectrum,
More informationMicrobiology : antimicrobial drugs. Sheet 11. Ali abualhija
Microbiology : antimicrobial drugs Sheet 11 Ali abualhija return to our topic antimicrobial drugs, we have finished major group of antimicrobial drugs which associated with inhibition of protein synthesis
More informationTOPICS. Continuing Education April 2014 Volume 16 Number 2. Journal of. Inside This Issue. Official publication of the American Medical Technologists
Journal of TOPICS & ISSUES Official publication of the American Medical Technologists Continuing Education April 2014 Volume 16 Number 2 Inside This Issue Back to the Future with Urinalysis: Part 2 A Confusing,
More informationUpdate on Resistance and Epidemiology of Nosocomial Respiratory Pathogens in Asia. Po-Ren Hsueh. National Taiwan University Hospital
Update on Resistance and Epidemiology of Nosocomial Respiratory Pathogens in Asia Po-Ren Hsueh National Taiwan University Hospital Ventilator-associated Pneumonia Microbiological Report Sputum from a
More informationChallenges Emerging resistance Fewer new drugs MRSA and other resistant pathogens are major problems
Micro 301 Antimicrobial Drugs 11/7/12 Significance of antimicrobial drugs Challenges Emerging resistance Fewer new drugs MRSA and other resistant pathogens are major problems Definitions Antibiotic Selective
More informationPreliminary Results of Bedaquiline as Salvage Therapy for Patients With Nontuberculous Mycobacterial Lung Disease
[ Original Research Chest Infections ] Preliminary Results of Bedaquiline as Salvage Therapy for Patients With Nontuberculous Mycobacterial Lung Disease Julie V. Philley, MD ; Richard J. Wallace Jr, MD,
More information56 Clinical and Laboratory Standards Institute. All rights reserved.
Table 2C 56 Clinical and Laboratory Standards Institute. All rights reserved. Table 2C. Zone Diameter and Minimal Inhibitory Concentration Breakpoints for Testing Conditions Medium: Inoculum: diffusion:
More informationAnimal models and PK/PD. Examples with selected antibiotics
Animal models and PK/PD PD Examples with selected antibiotics Examples of animal models Amoxicillin Amoxicillin-clavulanate Macrolides Quinolones Andes D, Craig WA. AAC 199, :375 Amoxicillin in mouse thigh
More informationACUTE EXACERBATIONS of COPD (AE-COPD) : The Belgian perspective
ACUTE EXACERBATIONS of COPD (AE-COPD) : The Belgian perspective Antwerpen 8 november 2002 Yvan Valcke MD PhD AZ Maria Middelares Sint-Niklaas ACUTE EXACERBATIONS of COPD (AE-COPD) Treatment of AECB Role
More informationThree Cases of Postoperative Septic Arthritis Caused by Mycobacterium. conceptionense in Shoulder Joints of Immunocompetent Patients
JCM Accepts, published online ahead of print on 3 January 2014 J. Clin. Microbiol. doi:10.1128/jcm.02652-13 Copyright 2014, American Society for Microbiology. All Rights Reserved. 1 2 Three Cases of Postoperative
More informationANTHRAX. INHALATION, INTESTINAL and CUTANEOUS ANTHRAX
INHALATION, INTESTINAL and CUTANEOUS ANTHRAX CPMP/4048/01, rev. 3 1/7 General points on treatment Anthrax is an acute infectious disease caused by Bacillus anthracis, that may be infecting man via cutaneous
More informationAntibiotics: mode of action and mechanisms of resistance. Slides made by Special consultant Henrik Hasman Statens Serum Institut
Antibiotics: mode of action and mechanisms of resistance. Slides made by Special consultant Henrik Hasman Statens Serum Institut This presentation Definitions needed to discuss antimicrobial resistance
More informationIntroduction to Pharmacokinetics and Pharmacodynamics
Introduction to Pharmacokinetics and Pharmacodynamics Diane M. Cappelletty, Pharm.D. Assistant Professor of Pharmacy Practice Wayne State University August, 2001 Vocabulary Clearance Renal elimination:
More informationRoutine internal quality control as recommended by EUCAST Version 3.1, valid from
Routine internal quality control as recommended by EUCAST Version.1, valid from 01-01-01 Escherichia coli Pseudomonas aeruginosa Staphylococcus aureus Enterococcus faecalis Streptococcus pneumoniae Haemophilus
More informationFeline Mycobacterial Infections Professor Danièlle Gunn-Moore University of Edinburgh
Feline Mycobacterial Infections Professor Danièlle Gunn-Moore University of Edinburgh INTRODUCTION Several species of mycobacteria can cause disease in veterinary species, being either primary pathogens,
More informationEUCAST-and CLSI potency NEO-SENSITABS
EUCASTand CLSI potency NEOSENSITABS Neo Sensitabs Page 1 / 6 Document: 6.2.0 Fastidious organisms EUCAST Interpretation zones and MIC breakpoints according to recommendations by the "Comité de l'antibiogramme
More informationPK/PD to fight resistance
PK/PD to fight resistance Eradicate Abnormal bacteria Mutations Efflux pumps Mutation-Preventing Concentration Breakpoint values for T > MIC and in practice With the support of Wallonie-Bruxelles-International
More informationAntibiotics & Resistance
What are antibiotics? Antibiotics & esistance Antibiotics are molecules that stop bacteria from growing or kill them Antibiotics, agents against life - either natural or synthetic chemicals - designed
More informationIntroduction to Antimicrobials. Lecture Aim: To provide a brief introduction to antibiotics. Future lectures will go into more detail.
Introduction to Antimicrobials Rachel J. Gordon, MD, MPH Lecture Aim: To provide a brief introduction to antibiotics. Future lectures will go into more detail. Major Learning Objectives: 1) Learn the different
More informationAntibacterial susceptibility testing
Antibiotics: Antil susceptibility testing are natural chemical substances produced by certain groups of microorganisms (fungi, ) that inhibit the growth of or kill the other that cause infection. Several
More informationMeasure Information Form
Release Notes: Measure Information Form Version 3.0b **NQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE** Measure Set: Pneumonia (PN) Performance Measure Identifier: Measure Information Form
More informationEfficacy of Colistin in combination with Carbapenem and Tigecycline in patients with pneumonia caused by multidrug-resistant Acinetobacter baumannii
Efficacy of Colistin in combination with Carbapenem and Tigecycline in patients with pneumonia caused by multidrug-resistant Acinetobacter baumannii Enty Tjoa 1, Frans Pangalila 2, Lucky H Moehario 1,
More informationAAC Accepts, published online ahead of print on 13 October 2008 Antimicrob. Agents Chemother. doi: /aac
AAC Accepts, published online ahead of print on 13 October 2008 Antimicrob. Agents Chemother. doi:10.1128/aac.01023-08 Copyright 2008, American Society for Microbiology and/or the Listed Authors/Institutions.
More informationEUCAST recommended strains for internal quality control
EUCAST recommended strains for internal quality control Escherichia coli Pseudomonas aeruginosa Staphylococcus aureus Enterococcus faecalis Streptococcus pneumoniae Haemophilus influenzae ATCC 59 ATCC
More informationMycobacterium wolinskyi Peritonitis after Peritoneal Catheter Embedment Surgery
doi: 10.2169/internalmedicine.8871-17 Intern Med 56: 3097-3101, 2017 http://internmed.jp CASE REPORT Mycobacterium wolinskyi Peritonitis after Peritoneal Catheter Embedment Surgery Hiroyuki Fujikura 1,
More informationMulti-Drug and Extensively Drug Resistant Tuberculosis
Multi-Drug and Extensively Drug Resistant Tuberculosis Gwen A. Huitt, M.D., M.S. Professor, Department of Medicine Director, Adult Infectious Disease Care Unit National Jewish Health Disclosures None Tuberculosis
More informationIn vitro antimycobacterial activity of the new quinolone OPC-17116
In vitro antimycobacterial activity of the new quinolone OPC-17116 Hajime Saito*, Haruaki Tomioka and Katsumasa Sato Department of Microbiology and Immunology, Shimane Medical University, 89-1, Enya-cho,
More informationAntimicrobial Susceptibility Summary 2017
Antimicrobial Susceptibility Summary 2017 Clinical Microbiology Department of Pathology & Laboratory Medicine Antimicrobial Susceptibility Summary Clinical Microbiology Department of Pathology and Laboratory
More informationMacrolides, Ketolides, and Glycylcyclines: Azithromycin, Clarithromycin, Telithromycin, Tigecycline
Macrolides, Ketolides, and Glycylcyclines: Azithromycin, Clarithromycin, Telithromycin, Tigecycline JerryM.Zuckerman, MD a,b, *,FoziaQamar, MD b, Bartholomew R.Bono, MD a,b KEYWORDS Macrolides Ketolides
More informationPeritonitis with Atypical Organisms
Peritonitis with Atypical Organisms Gurwant Kaur, MD Assistant Professor of Medicine (Nephrology) Co- director for Medical Students Renal block Penn State College of Medicine Penn State Milton S. Hershey
More informationAntibiotic Kinetic and Dynamic Attributes for Community-Acquired Respiratory Tract Infections
...PRESENTATIONS... Antibiotic Kinetic and Dynamic Attributes for Community-Acquired Respiratory Tract Infections David P. Nicolau, PharmD Presentation Summary Factors, including the age of the treatment
More informationChallenges to treat MDR TB
Challenges to treat MDR TB Manfred Danilovits Tartu University Hospital, Estonian NTP Program 2nd European Advanced Course in Clinical Tuberculosis 22-24 September 2014, Amsterdam MDR-TB control; WHO Europe,
More informationEuropean Committee on Antimicrobial Susceptibility Testing
European Committee on Antimicrobial Susceptibility Testing Routine and extended internal quality control for MIC determination and disk diffusion as recommended by EUCAST Version 8.0, valid from 018-01-01
More informationManagement of MDR and XDR TB Prof. Martin Boeree
Management of MDR and XDR TB 1, MD, PhD Associate Professor Consultant Respiratory Medicine Department of Lung Diseases Radboud University Nijmegen Medical Centre TB Referral Hospital Dekkerswald Nijmegen,
More informationConsiderations in antimicrobial prescribing Perspective: drug resistance
Considerations in antimicrobial prescribing Perspective: drug resistance Hasan MM When one compares the challenges clinicians faced a decade ago in prescribing antimicrobial agents with those of today,
More informationWORKSHOP 6 Towards European consensus indications for major antibiotic classes: an exercise with the macrolides. Objectives
Objectives To establish the basic pharmacokinetic properties and safety profile of predefined macrolides. To make an inventory of the intrinsic susceptibilities of pathogenic organisms towards macrolides
More informationETX2514SUL (sulbactam/etx2514) for the treatment of Acinetobacter baumannii infections
ETX2514SUL (sulbactam/etx2514) for the treatment of Acinetobacter baumannii infections Robin Isaacs Chief Medical Officer, Entasis Therapeutics Dr. Isaacs is a full-time employee of Entasis Therapeutics.
More informationReview of Macrolides (Azithromycin, Clarithromycin), Ketolids (Telithromycin) and Glycylcyclines (Tigecycline)
Review of Macrolides (Azithromycin, Clarithromycin), Ketolids (Telithromycin) and Glycylcyclines (Tigecycline) Jerry M. Zuckerman, MD a,b, *, Fozia Qamar, MD c,d, Bartholomew R. Bono, MD a,e KEYWORDS Macrolides
More informationChapter 51. Clinical Use of Antimicrobial Agents
Chapter 51 Clinical Use of Antimicrobial Agents History of antimicrobial therapy Early 17 th century Cinchona bark was used as an important historical remedy against malaria. 1909 Paul Ehrlich sought a
More informationIdentification of Cutaneous Mycobacterium massiliense Infections Associated with Repeated Surgical Procedures
Ann Dermatol Vol. 22, No. 1, 2010 DOI: 10.5021/ad.2010.22.1.114 CASE REPORT Identification of Cutaneous Mycobacterium massiliense Infections Associated with Repeated Surgical Procedures Ah Young Cho, M.D.,
More informationMechanisms and Pathways of AMR in the environment
FMM/RAS/298: Strengthening capacities, policies and national action plans on prudent and responsible use of antimicrobials in fisheries Final Workshop in cooperation with AVA Singapore and INFOFISH 12-14
More informationApproach to pediatric Antibiotics
Approach to pediatric Antibiotics Gassem Gohal FAAP FRCPC Assistant professor of Pediatrics objectives To be familiar with common pediatric antibiotics o Classification o Action o Adverse effect To discus
More informationAminoglycosides. Spectrum includes many aerobic Gram-negative and some Gram-positive bacteria.
Aminoglycosides The only bactericidal protein synthesis inhibitors. They bind to the ribosomal 30S subunit. Inhibit initiation of peptide synthesis and cause misreading of the genetic code. Streptomycin
More informationTopical Antibiotic Update. Brad Sutton, O.D., F.A.A.O. Indiana University School of Optometry Indianapolis Eye Care Center No financial disclosures
Topical Antibiotic Update Brad Sutton, O.D., F.A.A.O. Indiana University School of Optometry Indianapolis Eye Care Center No financial disclosures What do we have? We currently have many highly effective
More informationSaxena Sonal*, Singh Trishla* and Dutta Renu* (Received for publication January 2012)
J. Commun. Dis. 44(2) 2012 : 97-102 Practical disk diffusion method for detection of inducible clindamycin resistance in Staphylococcus aureus at a tertiary care hospital: Implications for clinical therapy
More informationStrategies for Successful Treatment of Drug Resistant Tuberculosis in the U.S.
Strategies for Successful Treatment of Drug Resistant Tuberculosis in the U.S. Barbara J. Seaworth, M.D. Professor of Medicine University of Texas Health Science Center, Tyler Medical Director, Heartland
More informationMultidrug-resistant Tuberculosis. Charles L. Daley, MD National Jewish Health Chair, Global GLC, WHO and Stop TB Partnership
Multidrug-resistant Tuberculosis Charles L. Daley, MD National Jewish Health Chair, Global GLC, WHO and Stop TB Partnership Disclosures World Health Organization Chair, Global GLC Otsuka Chair, Data Monitoring
More informationDrug-resistant TB therapy: the future is now
Drug-resistant TB therapy: the future is now Gary Maartens Thanks to Francesca Conradie for sharing slides Division of Clinical Pharmacology UNIVERSITY OF CAPE TOWN IYUNIVESITHI YASEKAPA UNIVERSITEIT VAN
More informationAntimicrobial Pharmacodynamics
Antimicrobial Pharmacodynamics November 28, 2007 George P. Allen, Pharm.D. Assistant Professor, Pharmacy Practice OSU College of Pharmacy at OHSU Objectives Become familiar with PD parameters what they
More informationAvailable online at Scholars Research Library. Der Pharmacia Lettre, 2017, 9 (1):85-92
Available online at www.scholarsresearchlibrary.com Scholars Research Library Der Pharmacia Lettre, 2017, 9 (1):85-92 (http://scholarsresearchlibrary.com/archive.html) ISSN 0975-5071 USA CODEN: DPLEB4
More informationمادة االدوية المرحلة الثالثة م. غدير حاتم محمد
م. مادة االدوية المرحلة الثالثة م. غدير حاتم محمد 2017-2016 ANTIMICROBIAL DRUGS Antimicrobial drugs Lecture 1 Antimicrobial Drugs Chemotherapy: The use of drugs to treat a disease. Antimicrobial drugs:
More informationESCMID Online Lecture Library. by author
Expert rules in susceptibility testing EUCAST-ESGARS-EPASG Educational Workshop Linz, 16 19 September, 2014 Dr. Rafael Cantón Hospital Universitario Ramón y Cajal SERVICIO DE MICROBIOLOGÍA Y PARASITOLOGÍA
More informationSMART WORKFLOW SOLUTIONS Introducing DxM MicroScan WalkAway System* ...
SMART WORKFLOW SOLUTIONS Introducing DxM MicroScan WalkAway System* The next-generation MicroScan WalkAway System combines proven technology and reliability with enhanced ease-of-use features to streamline
More informationWHY IS THIS IMPORTANT?
CHAPTER 20 ANTIBIOTIC RESISTANCE WHY IS THIS IMPORTANT? The most important problem associated with infectious disease today is the rapid development of resistance to antibiotics It will force us to change
More informationTB Intensive Houston, Texas. Multi-Drug Resistant (MDR) TB Barbara Seaworth, MD
TB Intensive Houston, Texas November 10-12, 12 2009 Multi-Drug Resistant (MDR) TB Barbara Seaworth, MD November 12, 2009 Multi-Drug Resistant (MDR) TB Updates November 12, 2009 Barbara J. Seaworth Professor
More informationRational management of community acquired infections
Rational management of community acquired infections Dr Tanu Singhal MD, MSc Consultant Pediatrics and Infectious Disease Kokilaben Dhirubhai Ambani Hospital, Mumbai Why is rational management needed?
More informationChemotherapy of bacterial infections. Part II. Mechanisms of Resistance. evolution of antimicrobial resistance
Chemotherapy of bacterial infections. Part II. Mechanisms of Resistance evolution of antimicrobial resistance Mechanism of bacterial genetic variability Point mutations may occur in a nucleotide base pair,
More informationActivity of a novel aminoglycoside, ACHN-490, against clinical isolates of Escherichia coli and Klebsiella pneumoniae from New York City
Journal of Antimicrobial Chemotherapy Advance Access published July 31, 2010 J Antimicrob Chemother doi:10.1093/jac/dkq278 Activity of a novel aminoglycoside, ACHN-490, against clinical isolates of Escherichia
More informationa. 379 laboratories provided quantitative results, e.g (DD method) to 35.4% (MIC method) of all participants; see Table 2.
AND QUANTITATIVE PRECISION (SAMPLE UR-01, 2017) Background and Plan of Analysis Sample UR-01 (2017) was sent to API participants as a simulated urine culture for recognition of a significant pathogen colony
More informationEDUCATIONAL COMMENTARY - Methicillin-Resistant Staphylococcus aureus: An Update
EDUCATIONAL COMMENTARY - Methicillin-Resistant Staphylococcus aureus: An Update Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain
More informationSubacute Adenitis. Ann M. Loeffler, MD
Subacute Adenitis Ann M. Loeffler, MD Lymphadenitis Swelling and hyperplasia of sinusoidal lining cells Infiltration of leukocytes +/- abscess formation Granulomatous or non-granulomatous Pyogenic adenitis
More informationجداول میکروارگانیسم های بیماریزای اولویت دار و آنتی بیوتیک های تعیین شده برای آزمایش تعیین حساسیت ضد میکروبی در برنامه مهار مقاومت میکروبی
جداول میکروارگانیسم های بیماریزای اولویت دار و آنتی بیوتیک های تعیین شده برای آزمایش تعیین حساسیت ضد میکروبی در برنامه مهار مقاومت میکروبی ویرایش دوم بر اساس ed., 2017 CLSI M100 27 th تابستان ۶۹۳۱ تهیه
More informationMDR treatment. Shanghai, May 2012 Arnaud Trébucq The Union
MDR treatment Shanghai, May 2012 Arnaud Trébucq The Union Why to diagnose MDR-TB? Outcome of SS+ new MDR-TB cases, treated with First Line TB (FLD) drugs Setting Success Died Fail LFFU Transf. Corea 20(56)
More informationInt.J.Curr.Microbiol.App.Sci (2018) 7(8):
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 7 Number 08 (2018) Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/10.20546/ijcmas.2018.708.378
More informationUpdated recommended treatment regimens for gonococcal infections and associated conditions United States, April 2007
Updated recommended treatment regimens for gonococcal infections and associated conditions United States, April 2007 1 Ongoing data from CDC 's Gonococcal Isolate Surveillance Project (GISP), including
More informationInternational Journal of Health Sciences and Research ISSN:
International Journal of Health Sciences and Research www.ijhsr.org ISSN: 2249-9571 Original Research Article Antibiotic Susceptibility Pattern of Pseudomonas Aeruginosa Isolated From Various Clinical
More informationBRUCELLOSIS BRUCELLOSIS. CPMP/4048/01, rev. 3 1/7 EMEA 2002
BRUCELLOSIS CPMP/4048/01, rev. 3 1/7 General points on treatment Four species are pathogenic to man: B. melitenis (acquired from goats), B. suis (pigs), B. abortus (cattle) and B. canis (dogs). The bacteria
More information